Maria Laura Amaya
Title | Assistant Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
Phone | 720/766-9786 |
---|
|
|
|
Research IK2BX005603 (AMAYA, MARIA LAURA)Apr 1, 2022 - Mar 31, 2027 NIH Identifying the Role of the IL-6/STAT3 Signaling Pathway in Higher-risk Myelodysplastic Syndrome Role: Principal Investigator |
| F31DK094650 (AMAYA, MARIA LAURA)Jul 25, 2012 - Jul 24, 2015 NIH The Role of Mi2/NuRD Complex on the Expression of Human Gamma-Globin Gene Role: Principal Investigator |
Bibliographic
-
Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study. Blood Cancer Discov. 2025 May 21. PMID: 40396900.
-
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon CM, Gutman J, Pollyea DA, Amaya ML. Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers. Leuk Lymphoma. 2025 Mar 13; 1-3. PMID: 40080662.
-
Amaya ML. A novel therapy with a rational design for AML. Blood. 2025 Jan 30; 145(5):457-458. PMID: 39883443.
-
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025 Jan 01; 110(1):103-116. PMID: 38934082.
-
Sheth AI, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug AE, Young TN, Minhajuddin M, Pei S, Patel SB, Winters A, Miller R, Shelton IT, St-Germain J, Ling T, Jones CL, Raught B, Gillen AE, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discov. 2024 Oct 04; 14(10):1922-1939. PMID: 38787341.
-
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mr?zek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446. PMID: 39367245.
-
Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, Bosma G, Pollyea DA, McMahon CM. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024 Dec; 65(14):2228-2230. PMID: 39229898.
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11. PMID: 39154914.
-
Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, Kaiser J, Abbott D, Pan Z, Schowinsky J, Pang C, Gutman JA, Pollyea DA. White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia. Leuk Lymphoma. 2024 Jun; 65(6):800-807. PMID: 38814858.
-
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69. PMID: 38394770.
-
Sheth AI, Engel K, Tolison H, Althoff MJ, Amaya ML, Krug A, Young T, Pei S, Patel SB, Minhajuddin M, Winters A, Miller R, Shelton I, St-Germain J, Ling T, Jones C, Raught B, Gillen A, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. bioRxiv. 2023 Oct 03. PMID: 37873284.
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625. PMID: 37051756.
-
Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 09 06; 13(9):2032-2049. PMID: 37358260.
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854. PMID: 37185614.
-
Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030. PMID: 36194842.
-
Nie Y, Kent A, Do M, Amaya M, Klein C, Thienelt C. Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery Embolization. Case Rep Oncol. 2022 Jan-Apr; 15(1):277-284. PMID: 35529292.
-
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 01 27; 139(4):584-596. PMID: 34525179.
-
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573. PMID: 34610123.
-
Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 06; 62(6):1466-1473. PMID: 33375853.
-
Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, D'Alessandro A, Jordan CT. The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discov. 2021 02; 11(2):500-519. PMID: 33028621.
-
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 11 05; 27(5):748-764.e4. PMID: 32822582.
-
Amaya ML, Jimeno A, Kamdar M. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs Today (Barc). 2020 Apr; 56(4):287-294. PMID: 32309823.
-
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551. PMID: 31974170.
-
Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019 12 23; 3(24):4326-4335. PMID: 31869416.
-
Amaya ML, Pollyea DA. Targeting the IDH2 Pathway in Acute Myeloid Leukemia. Clin Cancer Res. 2018 10 15; 24(20):4931-4936. PMID: 29769206.
-
Cheng CM, Amaya M, Butalia T, Baker R, Walker HW, Massey-Norton J, Wolfe W. Short-term influence of coal mine reclamation using coal combustion residues on groundwater quality. Sci Total Environ. 2016 Nov 15; 571:834-54. PMID: 27453136.
-
Amaya M, Desai M, Gnanapragasam MN, Wang SZ, Zu Zhu S, Williams DC, Ginder GD. Mi2?-mediated silencing of the fetal ?-globin gene in adult erythroid cells. Blood. 2013 Apr 25; 121(17):3493-501. PMID: 23444401.
-
Gnanapragasam MN, Scarsdale JN, Amaya ML, Webb HD, Desai MA, Walavalkar NM, Wang SZ, Zu Zhu S, Ginder GD, Williams DC. p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc Natl Acad Sci U S A. 2011 May 03; 108(18):7487-92. PMID: 21490301.
-
Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009 Jan; 7(1):171-81. PMID: 18983497.
-
Watts AG, Damager I, Amaya ML, Buschiazzo A, Alzari P, Frasch AC, Withers SG. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J Am Chem Soc. 2003 Jun 25; 125(25):7532-3. PMID: 12812490.
-
Amirkhosravi A, Amaya M, Desai H, Francis JL. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis. 2002 Sep; 13(6):505-12. PMID: 12192302.
-
Siddiqui FA, Amirkhosravi A, Amaya M, Desai H, Meyer T, Francis JL. Purification and properties of human melanoma cell tissue factor. Clin Appl Thromb Hemost. 2001 Oct; 7(4):289-95. PMID: 11697711.
-
Siddiqui FA, Amirkhosravi A, Amaya M, Meyer T, Biggerstaff J, Desai H, Francis JL. Hemoglobin enhances tissue factor expression on human malignant cells. Blood Coagul Fibrinolysis. 2001 Apr; 12(3):171-7. PMID: 11414630.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2001 | 2 | 2002 | 1 | 2003 | 1 | 2008 | 1 | 2011 | 1 | 2013 | 1 | 2016 | 1 | 2018 | 1 | 2019 | 1 | 2020 | 5 | 2021 | 1 | 2022 | 3 | 2023 | 4 | 2024 | 6 | 2025 | 4 |
To return to the timeline, click here.
|
Amaya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|